BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mohd-Ismail NK, Lim Z, Gunaratne J, Tan YJ. Mapping the Interactions of HBV cccDNA with Host Factors. Int J Mol Sci. 2019;20. [PMID: 31480501 DOI: 10.3390/ijms20174276] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Piracha ZZ, Saeed U, Kim J, Kwon H, Chwae YJ, Lee HW, Lim JH, Park S, Shin HJ, Kim K. An Alternatively Spliced Sirtuin 2 Isoform 5 Inhibits Hepatitis B Virus Replication from cccDNA by Repressing Epigenetic Modifications Made by Histone Lysine Methyltransferases. J Virol 2020;94:e00926-20. [PMID: 32493816 DOI: 10.1128/JVI.00926-20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
2 Ligat G, Goto K, Verrier E, Baumert TF. Targeting Viral cccDNA for Cure of Chronic Hepatitis B. Curr Hepatology Rep 2020;19:235-44. [DOI: 10.1007/s11901-020-00534-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
3 Prifti GM, Moianos D, Giannakopoulou E, Pardali V, Tavis JE, Zoidis G. Recent Advances in Hepatitis B Treatment. Pharmaceuticals (Basel) 2021;14:417. [PMID: 34062711 DOI: 10.3390/ph14050417] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Singh P, Kairuz D, Arbuthnot P, Bloom K. Silencing hepatitis B virus covalently closed circular DNA: The potential of an epigenetic therapy approach. World J Gastroenterol 2021; 27(23): 3182-3207 [PMID: 34163105 DOI: 10.3748/wjg.v27.i23.3182] [Reference Citation Analysis]
5 Chong RH, Khakpoor A, Tan TM, Lim SG, Lee GH. Liver-Derived Cell Transfection Model Efficacy for HBV Genotype B Replication/Transcription Is Determined by Complex Host Transcription Factor Network. Viruses 2021;13:524. [PMID: 33810128 DOI: 10.3390/v13030524] [Reference Citation Analysis]
6 Dandri M, Petersen J. cccDNA Maintenance in Chronic Hepatitis B - Targeting the Matrix of Viral Replication. Infect Drug Resist 2020;13:3873-86. [PMID: 33149632 DOI: 10.2147/IDR.S240472] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
7 Cai H, Liu G, Zhong J, Zheng K, Xiao H, Li C, Song X, Li Y, Xu C, Wu H, He Z, Zhu Q. Immune Checkpoints in Viral Infections. Viruses 2020;12:E1051. [PMID: 32967229 DOI: 10.3390/v12091051] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
8 Li W, Yu X, Chen X, Wang Z, Yin M, Zhao Z, Zhu C. HBV induces liver fibrosis via the TGF-β1/miR-21-5p pathway. Exp Ther Med 2021;21:169. [PMID: 33456536 DOI: 10.3892/etm.2020.9600] [Reference Citation Analysis]
9 Maepa MB, Bloom K, Ely A, Arbuthnot P. Hepatitis B virus: promising drug targets and therapeutic implications. Expert Opin Ther Targets 2021;25:451-66. [PMID: 33843412 DOI: 10.1080/14728222.2021.1915990] [Reference Citation Analysis]
10 Ding J, Wang J, Chen J. Exosomes as therapeutic vehicles in liver diseases. Ann Transl Med 2021;9:735. [PMID: 33987433 DOI: 10.21037/atm-20-5422] [Reference Citation Analysis]
11 Wang Y, Han M, Liu S, Yuan X, Zhao J, Lu H, Han K, Liang P, Cheng J. S6K1 inhibits HBV replication through inhibiting AMPK-ULK1 pathway and disrupting acetylation modification of H3K27. Life Sci 2021;265:118848. [PMID: 33278383 DOI: 10.1016/j.lfs.2020.118848] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
12 Qu B, Brown RJP. Strategies to Inhibit Hepatitis B Virus at the Transcript Level. Viruses 2021;13:1327. [PMID: 34372533 DOI: 10.3390/v13071327] [Reference Citation Analysis]
13 Dandri M. Epigenetic modulation in chronic hepatitis B virus infection. Semin Immunopathol 2020;42:173-85. [PMID: 32185454 DOI: 10.1007/s00281-020-00780-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 18.0] [Reference Citation Analysis]